Nivolumab in the Treatment of Advanced Renal Cell Carcinoma

References

• Ferlay J , SoerjomataramI, DikshitRet al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer136(5), e359–e386 (2015).
   PubMed Web of Science ®Google Scholar
• Dabestani S , ThorstensonA, LindbladP, HarmenbergU, LjungbergB, LundstamS. Renal cell carcinoma recurrences and metastases in primary non-metastatic patients: a population-based study. World J. Urol.34(8), 1081–1086 (2016).
   PubMed Web of Science ®Google Scholar
• Cohen HT , McGovernFJ. Renal-cell carcinoma. N. Engl. J. Med.353(23), 2477–2490 (2005).
   PubMed Web of Science ®Google Scholar
• Escudier B , PluzanskaA, KoralewskiPet al. Bevacizumab plus interferon α-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind Phase III trial. Lancet370(9605), 2103–2111 (2007).
   PubMed Web of Science ®Google Scholar
• Rini BI , HalabiS, RosenbergJEet al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J. Clin. Oncol.26(33), 5422–5428 (2008).
   PubMed Web of Science ®Google Scholar
• Motzer RJ , HutsonTE, TomczakPet al. Sunitinib versus interferon α in metastatic renal-cell carcinoma. N. Engl. J. Med.356(2), 115–124 (2007).
   PubMed Web of Science ®Google Scholar
• Sternberg CN , DavisID, MardiakJet al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized Phase III trial. J. Clin. Oncol.28(6), 1061–1068 (2010).
   PubMed Web of Science ®Google Scholar
• Rini BI , EscudierB, TomczakPet al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised Phase 3 trial. Lancet378(9807), 1931–1939 (2011).
   PubMed Web of Science ®Google Scholar
• Motzer RJ , EscudierB, OudardSet al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomised, placebo-controlled Phase III trial. Lancet372(9637), 449–456 (2008).
   PubMed Web of Science ®Google Scholar
• Hudes G , CarducciM, TomczakPet al. Temsirolimus, interferon α, or both for advanced renal-cell carcinoma. N. Engl. J. Med.356(22), 2271–2281 (2007).
   PubMed Web of Science ®Google Scholar
• Hanahan D , WeinbergRA. Hallmarks of cancer: the next generation. Cell144(5), 646–674 (2011).
   PubMed Web of Science ®Google Scholar
• Palucka K , BanchereauJ. Cancer immunotherapy via dendritic cells. Nat. Rev. Cancer12(4), 265–277 (2012).
   PubMed Web of Science ®Google Scholar
• Liu KG , GuptaS, GoelS. Immunotherapy: incorporation in the evolving paradigm of renal cancer management and future prospects. Oncotarget8(10), 17313–17327 (2017).
   PubMedGoogle Scholar
• Tupikowski K , PartykaA, KolodziejAet al. CTLA-4 and CD28 genes’ polymorphisms and renal cell carcinoma susceptibility in the Polish population – a prospective study. Tissue Antigens86(5), 353–361 (2015).
   PubMedGoogle Scholar
• Riella LV , PatersonAM, SharpeAH, ChandrakerA. Role of the PD-1 pathway in the immune response. Am. J. Transplant.12(10), 2575–2587 (2012).
   PubMed Web of Science ®Google Scholar
• Wherry EJ . T cell exhaustion. Nat. Immunol.12(6), 492–499 (2011).
   PubMed Web of Science ®Google Scholar
• Munn DH , MellorAL. IDO in the tumor microenvironment: inflammation, counter-regulation, and tolerance. Trends Immunol.37(3), 193–207 (2016).
   PubMed Web of Science ®Google Scholar
• Mellman I , CoukosG, DranoffG. Cancer immunotherapy comes of age. Nature480(7378), 480–489 (2011).
   PubMed Web of Science ®Google Scholar
• Drake CG , JaffeeE, PardollDM. Mechanisms of immune evasion by tumors. Adv. Immunol.90, 51–81 (2006).
   PubMed Web of Science ®Google Scholar
• Pardoll DM . The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer12(4), 252–264 (2012).
   PubMed Web of Science ®Google Scholar
• Opdivo®, prescribing information. Bristol-Myers Squibb Co., NJ, USA (2017).
   Google Scholar
• Brahmer JR , DrakeCG, WollnerIet al. Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. J. Clin. Oncol.28(19), 3167–3175 (2010).
   PubMed Web of Science ®Google Scholar
• Topalian SL , HodiFS, BrahmerJRet al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med.366(26), 2443–2454 (2012).
   PubMed Web of Science ®Google Scholar
• Mcdermott DF , DrakeCG, SznolMet al. Survival, durable response, and long-term safety in patients with previously treated advanced renal cell carcinoma receiving nivolumab. J. Clin. Oncol.33(18), 2013–2020 (2015).
   PubMed Web of Science ®Google Scholar
• Motzer RJ , RiniBI, McDermottDFet al. Nivolumab for metastatic renal cell carcinoma: results of a randomized Phase II trial. J. Clin. Oncol.33(13), 1430–1437 (2015).
   PubMed Web of Science ®Google Scholar
• Motzer RJ , EscudierB, McDermottDFet al. Nivolumab versus everolimus in advanced renal-cell carcinoma. N. Engl. J. Med.373(19), 1803–1813 (2015).
   PubMed Web of Science ®Google Scholar
• Escudier BT , McDermottNM, FronteraDFet al. CheckMate 214: efficacy and safety of nivolumab + ipilimumab (N+I) v sunitinib (S) for treatment-naive advanced or metastatic renal cell carcinoma (mRCC), including IMDC risk and PD-L1 expression subgroups. Ann. Oncol.28(Suppl. 5), mdx440.029 (2017).
   Google Scholar
• Thompson RH , DongH, LohseCMet al. PD-1 is expressed by tumor-infiltrating immune cells and is associated with poor outcome for patients with renal cell carcinoma. Clin. Cancer Res.13(6), 1757–1761 (2007).
   PubMed Web of Science ®Google Scholar
• Thompson RH , KuntzSM, LeibovichBCet al. Tumor B7-H1 is associated with poor prognosis in renal cell carcinoma patients with long-term follow-up. Cancer Res.66(7), 3381–3385 (2006).
   PubMed Web of Science ®Google Scholar
• Choueiri TK , FishmanMN, EscudierBet al. Immunomodulatory activity of nivolumab in metastatic renal cell carcinoma. Clin. Cancer Res.22(22), 5461–5471 (2016).
   PubMed Web of Science ®Google Scholar
• Snyder A , MakarovV, MerghoubTet al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N. Engl. J. Med.371(23), 2189–2199 (2014).
   PubMed Web of Science ®Google Scholar
• Rizvi NA , HellmannMD, SnyderAet al. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer. Science348(6230), 124–128 (2015).
   PubMed Web of Science ®Google Scholar
• Goodman AM , KatoS, BazhenovaLet al. Tumor mutational burden as an independent predictor of response to immunotherapy in diverse cancers. Mol. Cancer Ther.16(11), 2598–2608 (2017).
   PubMed Web of Science ®Google Scholar
• Larkin J , HodiFS, WolchokJD. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med.373(13), 1270–1271 (2015).
   PubMed Web of Science ®Google Scholar
• Hammers HJ , PlimackER, InfanteJRet al. Safety and efficacy of nivolumab in combination with ipilimumab in metastatic renal cell carcinoma: the CheckMate 016 study. J. Clin. Oncol.35(34), 3851–3858 (2017).
   PubMed Web of Science ®Google Scholar
• Motz GT , CoukosG. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat. Rev. Immunol.11(10), 702–711 (2011).
   PubMed Web of Science ®Google Scholar
• Hodi FS , LawrenceD, LezcanoCet al. Bevacizumab plus ipilimumab in patients with metastatic melanoma. Cancer Immunol. Res.2(7), 632–642 (2014).
   PubMed Web of Science ®Google Scholar
• Noman MZ , ChouaibS. Targeting hypoxia at the forefront of anticancer immune responses. Oncoimmunology3(12), e954463 (2014).
   PubMed Web of Science ®Google Scholar
• Yasuda S , ShoM, YamatoIet al. Simultaneous blockade of programmed death 1 and vascular endothelial growth factor receptor 2 (VEGFR2) induces synergistic anti-tumour effect in vivo. Am. J. Clin. Exp. Immunol.172(3), 500–506 (2013).
   PubMed Web of Science ®Google Scholar
• Zhao X , SuryawanshiS, HruskaMet al. Assessment of nivolumab benefit-risk profile of a 240-mg flat dose relative to a 3-mg/kg dosing regimen in patients with advanced tumors. Ann. Oncol.28(8), 2002–2008 (2017).
   PubMed Web of Science ®Google Scholar
• Amin A , PlimackER, InfanteJRet al. Nivolumab (anti-PD-1; BMS-936558, ONO-4538) in combination with sunitinib or pazopanib in patients (pts) with metastatic renal cell carcinoma (mRCC). J. Clin. Oncol.32(Suppl. 15), 5010 (2014).
   Google Scholar
• George S , MotzerRJ, HammersHJet al. Safety and efficacy of nivolumab in patients with metastatic renal cell carcinoma treated beyond progression: a subgroup analysis of a randomized clinical trial. JAMA Oncol.2(9), 1179–1186 (2016).
   PubMed Web of Science ®Google Scholar
• Escudier B , MotzerRJ, SharmaPet al. Treatment beyond progression in patients with advanced renal cell carcinoma treated with nivolumab in CheckMate 025. Eur. Urol.72(3), 368–376 (2017).
   PubMed Web of Science ®Google Scholar
• Bajaj G , WangX, AgrawalS, GuptaM, RoyA, FengY. Model-based population pharmacokinetic analysis of nivolumab in patients with solid tumors. CPT Pharmacometrics Syst. Pharmacol.6(1), 58–66 (2017).
   PubMedGoogle Scholar
• Choueiri TK , FayAP, GrayKPet al. PD-L1 expression in nonclear-cell renal cell carcinoma. Ann. Oncol.25(11), 2178–2184 (2014).
   PubMed Web of Science ®Google Scholar
• Geynisman DM . Anti-programmed cell death protein 1 (PD-1) antibody nivolumab leads to a dramatic and rapid response in papillary renal cell carcinoma with sarcomatoid and rhabdoid features. Eur. Urol.68(5), 912–914 (2015).
   PubMed Web of Science ®Google Scholar
• Ruiz-Banobre J , AnidoU, AbdulkaderI, Antunez-LopezJ, Lopez-LopezR, Garcia-GonzalezJ. Long-term response to nivolumab and acute renal failure in a patient with metastatic papillary renal cell carcinoma and a PD-L1 tumor expression increased with sunitinib therapy: a case report. Front. Oncol.6, 250 (2016).
   PubMed Web of Science ®Google Scholar
• Rimar KJ , MeeksJJ, KuzelTM. Anti-programmed death receptor 1 blockade induces clinical response in a patient with metastatic collecting duct carcinoma. Clin. Genitourin. Cancer14(4), e431–e434 (2016).
   PubMed Web of Science ®Google Scholar
• Rouvinov K , OsyntsovL, Shaco-LevyR, BaramN, AriadS, MermershtainW. Rapid response to nivolumab in a patient with sarcomatoid transformation of chromophobe renal cell carcinoma. Clin. Genitourin. Cancer15(6), e1127–e1130 (2017).
   PubMed Web of Science ®Google Scholar
• Koshkin VS , BarataPC, VogelzangNJet al. Nivolumab treatment for patients with non-clear cell renal cell carcinoma: a multicenter retrospective analysis. J. Clin. Oncol.35(Suppl. 15), 4586 (2017).
   Google Scholar
• Moreira RB , MckayRR, XieWet al. Clinical activity of PD1/PDL1 inhibitors in metastatic non-clear cell renal cell carcinoma (nccRCC). J. Clin. Oncol.35(Suppl. 6), 482 (2017).
   PubMedGoogle Scholar